Modern drug approaches to glycemic control in patients with type 1 and 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The basis of the treatment of patients with type1 and type 2 diabetes mellitus (DM1 and DM2) is the glycemic control with the use of modern hypoglycemic drugs; lifestyle changes and the organoprotective treatment approaches are also widely used. The objective of this report is to review the principles of drug control of glycemia in diabetic patients. The article describes modern aspects of the use of antihyperglycemic therapy in DM1 and DM2 patients. Special attention is paid to the efficacy and safety of the use of hypoglycemic agents both as monotherapy and in various combinations for diabetic patients with comorbid conditions. The presence of diabetes is associated with the development of severe forms of coronavirus infection. Diabetic patients have a higher rate of progression of pneumonia; respiratory distress syndrome, acute kidney injury, septic shock, and disseminated intravascular coagulation are more common. The article presents modern data on the features of managing diabetic patients in the context of the COVID-19 pandemic (preventive and therapeutic approaches), which makes this work highly relevant for practical healthcare.

Full Text

Restricted Access

About the authors

A. E Bagriy

M. Gorky Donetsk State Medical University

Donetsk, Donetsk People's Republic

E. V Shchukina

M. Gorky Donetsk State Medical University

Donetsk, Donetsk People's Republic

V. A Efremenko

M. Gorky Donetsk State Medical University

Donetsk, Donetsk People's Republic

Evgeniya S. Mikhailichenko

M. Gorky Donetsk State Medical University

Email: klassiki@inbox.ru
Cand. Sci. (Med.), Teaching Assistant at the Department of Internal Diseases № 2 16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic

E. V Suprun

Railway Clinical Hospital of Donetsk station

Donetsk, Donetsk People's Republic

References

  1. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых. Клинические Рекомендации. Сахарный диабет. 2020;23(S2):4-102. doi: 10.14341/DM23S2.
  2. American Diabetes Association. ADA Standards of Medical Care in Diabetes- 2021. Diabetes Care. 2021;44(Suppl.1):S1-232. doi: 10.2337/dc21-S001.
  3. Neumiller J.J., Bakris G., Cefalu W.T., et al. Professional Practice Committee: Standards of Medical Care in Diabetes, 2020. Diabetes Care. 2020;43(S1): S3. doi: 10.2337/dc20-SPPC.
  4. Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10): 4-13. doi: 10.26442/00403660.2019.10.0 00364.
  5. Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
  6. Hinchliffe R.J., Forsythe R.O., Apelqvist J., et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (iWGDF 2019 update). Diab Metab Res Rev. 2020;36:e3276. doi: 10.1002/dmrr.3276.
  7. Norris J.M., Johnson R.K., Stene L.C. Type 1 diabetes - early life origins and changing epidemiology Lancet Diab Endocrinol. 2020;8(3):226-38. doi: 10.1016/S2213-8587(19)30412-7.
  8. DiMeglio L.A., Evans-Molina C., Oram R.A. Type 1 diabetes. Lancet. 2018;391(10138):2449-62. doi: 10.1016/S0140-6736(18)31320-5.
  9. Maiorino M.i., Signoriello S., Maio A., et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with metaanalysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146-56. doi: 10.2337/dc19-1459.
  10. Pearson E.R. Type 2 diabetes: a multifaceted disease. Diabetologia. 2019;62(7):1107-12. doi: 10.1007/s00125-019-4909-y.
  11. Garber A.J., Handelsman Y., Grunberger G., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract. 2020;26(1):107-39. doi: 10.4158/CS-2019-0472.
  12. Дудинская Е.Н. Возможности комбинированной сахароснижающей терапии у пожилых лиц с сахарным диабетом 2 типа. Русский медицинский журнал. 2019;4:38-43.
  13. Черникова Н.А., Кнышенко О.А. Современные подходы к выбору сахароснижающей терапии у пациентов с сахарным диабетом 2 типа: ниша ингибиторов ДПП-4. Фарматека. 2020;27(4):33-9. doi: 10.18565/pharmateca.2020.4.33-39.
  14. Демидова Т.Ю. Лечение больных сахарным диабетом 2 типа и коморбидными заболеваниями. Что необходимо знать практикующему врачу? Русский медицинский журнал. Медицинское обозрение. 2019;10(II):123-26.
  15. Foretz M., Guigas B., Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569-89. doi: 10.1038/s41574-019-0242-2.
  16. Багрий А.Э., Супрун Е.В., Михайличенко Е.С. и др. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал. 2020;25(4):3858. doi: 10.15829/1560-4071-2020-3858.
  17. Глинкина И.В. Использование современных ультракоротких аналогов инсулина в лечении сахарного диабета 2 типа. Русский медицинский журнал. Медицинское обозрение. 2019;1(i):26-30.
  18. Ojha A., Ojha U., Mohammed R., et al. Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. Clin Pharmacol Adv Applicat. 2019;11:57-65. doi: 10.2147/CPAA.S202614.
  19. Guo W., Li M., Dong Y., et al. Diabetes is a risk factor for the progression and prognosis of COViD-19. Diab Metab Res Rev. 2020;36(7):e3319. Doi: org/10.1002/dmrr.3319.
  20. Singh A.K., Gupta R., Ghosh A., et al. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clin Res Rev. 2020;14(4):303-10. doi: 10.1016/j.dsx.2020.04.004.
  21. Gregory J.M., Slaughter J.C., Duffus S.H., et al. COVID-19 Severity is Tripled in the Diabetes Community: A Prospective analysis of the Pandemic's impact in Type 1 and Type 2 Diabetes. Diab Care. 2021;44(2):526-32. doi: 10.2337/dc20-2260.
  22. Шестакова М.В., Викулова О.К., Исаков М.А., Дедов И.И. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации. Проблемы эндокринологии. 2020;66(1):35-46. doi: 10.14341/probl12458.
  23. Бабенко А.Ю., Лаевская М.Ю. Сахарный диабет и COVID-19. Как они связаны? Современные стратегии борьбы. Артериальная гипертензия. 2020;26(3):304-11. doi: 10.18705/1607-419X-2020-26-3-304-311.
  24. Шестакова М.В., Мокрышева Н.Г, Дедов И.И. Сахарный диабет в условиях вирусной пандемии COVID-19: особенности течения и лечения. Сахарный диабет. 2020;23(2):132-139. doi: 10.14341/DM12418.
  25. Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-18. doi: 10.1016/S0140-6736(20)30937-5.
  26. Шамхалова М.Ш., Мокрышева Н.Г, Шестакова М.В. COVID-19 и почки. Сахарный диабет. 2020;23(3):235-41. doi: 10.14341/DM12506.
  27. Pascarella G., Strumia A., Piliego C., et al. COVID 19 diagnosis and management: a comprehensive review. J int Med. 2020;288(2):192-206. doi: 10.1111/joim.13091.
  28. Ali i., Alharbi O.M. COVID-19: Disease, management, treatment, and social impact. Sci Total Environm. 2020;728:138861. doi: 10.1016/j.scitotenv.2020.138861.
  29. Министерство здравоохранения Российской Федерации. Рекомендации, временные методические. «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 10 (08.02.2021). М., 2020.
  30. Rayman G., Lumb A., Kennon B., et al. London inpatient Diabetes Network-COVID-19. Guidelines for the management of diabetes services and patients during the COVID-19 pandemic. Diab Med. 2020;37(7):1087-89. doi: 10.1111/dme.14316.
  31. Sinclair A., Dhatariya K., Bur, O., et al. Guidelines for the management of diabetes in care homes during the COVID-19 pandemic. Diab Med. 2020;37(7):1090-93. doi: 10.1111/dme.14317.
  32. Tornese G., Ceconi V., Monasta L., et al. Glycemic control in type 1 diabetes mellitus during COVID-19 quarantine and the role of in-home physical activity. Diab Technol Therap. 2020;22(6):462-67. doi: 10.1089/dia.2020.0169.
  33. Gupta R., Ghosh A., Singh A.K., et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diab Metab Syndr. 2020;14(3):211-12. doi: 10.1016/j.dsx.2020.03.002.
  34. Громова Ю.М., Бова А.А. Некоторые аспекты ведения пациентов с сахарным диабетом при инфекции COVID-19. Медицинские новости. 2020;9(312):29-31.
  35. Мокрышева Н.Г., Галстян Г.Р., Киржаков М.А. и др. Пандемия COVID-19 и эндокринопатии. Проблемы эндокринологии. 2020;66(1):7-13. doi: 10.14341/probl12376.
  36. Gupta A. Real-world clinical effectiveness and tolerability of hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who are not willing to initiate insulin therapy (HYQ-Real-World Study). Curr Diab Rev. 2019;15(6): 510-19. doi: 10.2174/1573399815666190425 182008.
  37. Xu M., Yang W., Huang T., et al. Diabetic patients with COVID-19 need more attention and better glycemic control. World J Diab. 2020;11(12):644-53. doi: 10.4239/wjd.v11.i12.644.
  38. Crouse A.B., Grimes T., Li P., et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol. 2021;11:1081. doi: 10.3389/fendo.2020.600439.
  39. Bonora B.M., Avogaro A., Fadini, G.P Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol invest. 2021:1-8. doi: 10.1007/s40618-021-01515-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies